Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
We can see a decrease in the price for Rhythm Pharmaceuticals. Compared to yesterday it has lost -€1.500 (-1.680%).
With 36 Buy predictions and 1 Sell predictions Rhythm Pharmaceuticals is one of the favorites of our community.
As a result the target price of 116 € shows a positive potential of 31.82% compared to the current price of 88.0 € for Rhythm Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Rhythm Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -1.680% | -8.556% | -13.198% | 14.765% | -8.556% | 292.202% | 519.565% |
| Evolus Inc | -0.880% | -7.848% | -16.214% | -35.039% | -8.220% | -44.729% | -46.787% |
| Heron Therapeutics Inc. | -1.530% | 6.405% | 19.806% | -69.444% | -60.036% | -70.121% | -95.572% |
| Champions Oncology Inc | 2.690% | -13.398% | -13.398% | -15.048% | -23.103% | -21.754% | -48.736% |
Comments
Rhythm Pharmaceuticals (RYTM) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $145.00 price target on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its "buy" rating reaffirmed by TD Cowen.
Show more
Ratings data for RYTM provided by MarketBeat